Skip to Content
DAEWOONG PHARMACEUTICAL CO.LTD.
About Daewoong
About Daewoong
Global Network
Company Culture
History
Ethics
Contact Us
R&D
R&D Centers
R&D Projects
Achievements
Research Result
Platform Technology
Manufacturing Capabilities
Plants
Smart Factory
FDF CDMO
Product
Biologics
Chemicals
CTD List
Newsroom
Press Release
PR Videos
Investors
Overview
Corporate Governance
Annual Reports
Stock Info
IR
Careers
EN
KR
EN
View all menu
About Daewoong
About Daewoong
Our Purpose
CEO Message
Affiliates
Global Network
Company Culture
History
Ethics
Compliance Program
CEO Message
CP Rating
CP Activities
Contact Us
R&D
R&D Centers
R&D Projects
Achievements
Research Result
Platform Technology
Manufacturing
Capabilities
Plants
Smart Factory
FDF CDMO
Product
Biologics
Chemicals
CTD List
Newsroom
Press Release
PR Videos
Investors
Overview
Corporate Governance
Overview
Board of Directors
Stockholder Info
Stockholder's meeting
Annual Reports
Balance Sheet
Income Statement
Credit Rating
Stock Info
Stock Info
Stock Status
IR
Events & Presentations
Earnings announcement
FAQ
Careers
Daewoong
Global Healthcare Group
The Best Partner for You
Plants
Pan-Global Specialized Manufacturing Capabilities
Korea
Global
Korea
Korea Plants
Daewoong Pharmaceutical has a number of
strategically located manufacturing sites, each of
which specializes in various production lines
such as depot, liquid suspension, biologics, and etc.
Osong Plant
Chungcheongbuk-do, South Korea
Feature
Highly automated mass production facility
Qualified injection manufacturing facility
Depot injection & ampoule, vial, drip infusion kit
First in Korea to be equipped with Dual Chamber
Syringe (DCS) charging line)
Capacity: Dual Chamber Syringe (0.35M), Prefilled
Syringe (0.25M), Tablet (2B)
Area
40,892 m
2
(440,158 ft
2
)
Manufacturing Products
Oral Solid, Depot Injection, Vial, Ampoule
Hyangnam
Plant
Hyangnam, South Korea
Feature
Main manufacturing site for oral solids,
suspensions, injectables and biologics
Produces Korea’s first new biomedicine ‘EGF’
(Epidermal Growth Factor)
Supports clinical trial(phase 1-3) batch sizes
and clinical scale-up manufacturing
Capacity: Tablet (1B), Prefilled Syringe (1M)
Area
31,735 m
2
(341,598 ft
2
)
Manufacturing Products
Oral Solid, Microbial Product,
Cell cultured Product
Seongnam
Daewoong-Bio
Plant
Seongnam, South Korea
Feature
Top cephalosporin CMO facility
RABS (Restricted-access barrier system) ensures
sterility and validated aseptic-quality products
Capacity: Powder Injection Filling Line (24M Vial),
Tablet (100M), Capsule (100M)
Area
7,535 m
2
(81,106 ft
2
)
Manufacturing Products
Cephalosporin Injection, Tablet, Capsule
Anseong
Daewoong-Bio
Plant
Anseong, South Korea
Area
8,180 m
2
(88,048 ft
2
)
Manufacturing Products
Oral Solid
Daejeon Plant
(HANALL BIOPHARMA)
Daejeon, South Korea
Area
9,011 m
2
(96,993 ft
2
)
Manufacturing Products
A/A infusion, Oral Solid